Gerard Michel, Chief Executive Officer of Delcath Systems, Inc., has been appointed as an independent member of the board of directors for Beta Bionics, Inc., effective March 26, 2025. Beta Bionics is a medical device company focused on diabetes management solutions.
Mr. Michel brings over 30 years of experience in the pharmaceutical and medical technology industries to his new role. His background includes leadership positions as Chief Financial Officer at Vericel Corporation, Biodel, Inc., and NPS Pharmaceuticals Inc.
This appointment highlights Mr. Michel's recognized expertise in driving innovation and commercial success within the life sciences sector. His contributions are expected to be valuable to Beta Bionics as it scales its commercial footprint and advances its innovation pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.